Y
Yaling Hu
Researcher at Sinovac Biotech
Publications - 16
Citations - 3199
Yaling Hu is an academic researcher from Sinovac Biotech. The author has contributed to research in topics: Medicine & Antibody. The author has an hindex of 7, co-authored 9 publications receiving 1533 citations.
Papers
More filters
Journal ArticleDOI
Development of an inactivated vaccine candidate for SARS-CoV-2.
Qiang Gao,Linlin Bao,Haiyan Mao,Lin Wang,Kangwei Xu,Minnan Yang,Li Yajing,Ling Zhu,Nan Wang,Zhe Lv,Hong Gao,Ge Xiaoqin,Biao Kan,Yaling Hu,Jiangning Liu,Fang Cai,Deyu Jiang,Yanhui Yin,Cheng-Feng Qin,Jing Li,Xuejie Gong,Xiuyu Lou,Wen Shi,Dongdong Wu,Hengming Zhang,Zhu Lang,Wei Deng,Li Yurong,Jinxing Lu,Changgui Li,Xiangxi Wang,Weidong Yin,Yanjun Zhang,Chuan Qin +33 more
TL;DR: Preclinical results of an early vaccine candidate called PiCoVacc, which protected rhesus macaque monkeys against SARS-CoV-2 infection when analyzed in short-term studies, support the clinical development and testing of Pi coVacc for use in humans.
Journal ArticleDOI
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial.
Yanjun Zhang,Gang Zeng,Hongxing Pan,Changgui Li,Yaling Hu,Kai Chu,Weixiao Han,Zhen Chen,Rong Tang,Weidong Yin,Xin Chen,Yuansheng Hu,Xiao-Yong Liu,Cong-Bing Jiang,Jingxin Li,Minnan Yang,Yan Song,Xiangxi Wang,Qiang Gao,Fengcai Zhu +19 more
TL;DR: The primary safety endpoint was adverse reactions within 28 days after injection in all participants who were given at least one dose of study drug (safety population).
Journal ArticleDOI
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial.
Zhi-Wei Wu,Yaling Hu,Miao Xu,Zhen Chen,Wanqi Yang,Zhiwei Jiang,Minjie Li,Hui Jin,Guo-Liang Cui,Panpan Chen,Lei Wang,Guoqing Zhao,Yuzhu Ding,Yu-Liang Zhao,Weidong Yin +14 more
TL;DR: In this paper, the safety, tolerability, and immunogenicity of a COVID-19 vaccine, CoronaVac, containing inactivated SARS-CoV-2, in adults aged 60 years and older was evaluated.
Journal ArticleDOI
SARS-CoV-2 spike protein interacts with and activates TLR41.
Journal ArticleDOI
Memory B cell repertoire from triple vaccinees against diverse SARS-CoV-2 variants
Kang-Sheng Wang,Zijing Jia,Linilin Bao,Lei Wang,Lei Cao,Hang Chi,Yaling Hu,Qianqian Li,Yunjiao Zhou,Yi-Fan Jiang,Qianhui Zhu,Yong-Qiang Deng,Pan Liu,Nan Wang,Lin Wang,Min Liu,Yurong Li,Boling Zhu,Kaiyue Fan,Wangjun Fu,Peng-Yu Yang,Xin-Guo Pei,Zhen Cui,Lili Qin,Pingju Ge,Jiajing Wu,Shuo Liu,Yi-da Chen,Weijin Huang,Qiao-gang Wang,Cheng-Feng Qin,Youchun Wang,Chuan Qin,Xiangxi Wang +33 more
TL;DR: In this article , the authors examined whether sera from individuals who received two or three doses of inactivated SARS-CoV-2 vaccine could neutralize authentic Omicron.